Hyphens Pharma International eyes Catalist listing

Singapore

HYPHENS Pharma International is seeking a listing on the Catalist board of the Singapore Exchange, with part of the proceeds from the inital public offering (IPO) to go towards expansion.

The pharmaceutical and consumer healthcare group's core business segments include speciality pharmaceutical products, proprietary brands such as Ceradan and Ocean Health supplements, as well as a wholesale medical hypermart and digital business.

The IPO will comprise a cornerstone offering as well as a placement and a public offering, according to the preliminary offer document. Of the placement shares, a certain number of reserved shares will be kept for subscription by the company's directors and employees, its subsidiaries as well as business associates a…